Cargando…

S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME

Detalles Bibliográficos
Autores principales:	Frustaci, Anna Maria, Montillo, Marco, Rossi, Davide, Zinzani, Pier Luigi, Motta, Marina, Gaidano, Gianluca, Quaresmini, Giulia, Scarfò, Lydia, Pietrasanta, Daniela, Coscia, Marta, Deodato, Marina, Zamprogna, Giulia, Cairoli, Roberto, Stüssi, Georg, Zucca, Emanuele, Pileri, Stefano, Zenz, Thorsten, Tedeschi, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428250/ http://dx.doi.org/10.1097/01.HS9.0000967500.69905.66

Ejemplares similares

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

The Occurrence of Richter's Syndrome during Treatment with Obinutuzumab and Chlorambucil
por: Ng, Teng Fong, et al.
Publicado: (2020)

Allegro molto : 60 años de anécdotas musicales
por: Páramo, José Alfredo
Publicado: (2010)

Molto adagio Quatuor avec piano ; Larghetto ; Adagio ; Trois poémes /
por: Lekeu, Guillaume, 1870-1894
Publicado: (1994)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells
por: Trojani, Alessandra, et al.
Publicado: (2021)

Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter’s Syndrome
por: Heyman, Benjamin M., et al.
Publicado: (2022)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Un anno molto verde e senza fili
Publicado: (2008)

Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022)

Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)

Richter Syndrome: From Molecular Pathogenesis to Druggable Targets
por: Mouhssine, Samir, et al.
Publicado: (2022)

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2015)

Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy
por: Mahmoud, Abdurraouf Mokhtar, et al.
Publicado: (2023)

Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy: On behalf of CLL commission of Lombardy Hematology Network (REL)
por: Reda, Gianluigi, et al.
Publicado: (2020)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2022)

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial
por: Morschhauser, Franck, et al.
Publicado: (2021)

Sviatoslav Richter
Publicado: (1998)

Sviatoslav Richter.
por: Beethoven, Ludwig van, 1770-1827
Publicado: (1998)

Richter Syndrome
por: Condoluci, Adalgisa, et al.
Publicado: (2021)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

The involvement of microRNA in the pathogenesis of Richter syndrome
por: Van Roosbroeck, Katrien, et al.
Publicado: (2019)

Honouring Burton Richter
Publicado: (2000)

The psychobiology of Curt Richter
Publicado: (1977)

Periorbital Richter Syndrome
por: Gorman, Mark, et al.
Publicado: (2015)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

Clonally unrelated Richter syndrome are truly de novo diffuse large B‐cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome
por: Favini, Chiara, et al.
Publicado: (2022)

Biology and Treatment of Richter Transformation
por: Condoluci, Adalgisa, et al.
Publicado: (2022)

Cytogenomic features of Richter transformation
por: Woroniecka, Renata, et al.
Publicado: (2023)

Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
por: Fabbri, Giulia, et al.
Publicado: (2013)

Disseminated Enteroviral Infection Associated with Obinutuzumab
por: Dendle, Claire, et al.
Publicado: (2015)

Burton Richter à l'honneur
Publicado: (2000)

Richter's syndrome: a novel presentation.
por: Smyth, E. F., et al.
Publicado: (2003)

A Celebration Honoring Burton Richter
por: Collective
Publicado: (2000)

A Case of Richter's Strangulated Hernia
por: Moore, C. A.
Publicado: (1914)

Extranodal Richter's syndrome of the urinary bladder
por: Carrión-Valencia, Almudena, et al.
Publicado: (2018)

Current trends in the management of Richter's syndrome
por: Allan, John N, et al.
Publicado: (2019)

Immunochemotherapy for Richter syndrome: current insights
por: Puła, Bartosz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kbr70cet9p1lltf5fl4e248scn